Particle Sciences Expands its cGMP Capabilities with the Addition of Thin Films

BETHLEHEM, Pa., June 6, 2012-- Particle Sciences, a leading drug delivery CRO, has added new coating capabilities for preparing polymer film-based drug products from liquid formulations, under cGMPs. According to Garry Gwozdz, Director, Formulation Services, "Particle Sciences' purpose is to provide our clients with the most efficient drug product. Increasingly, we are seeing a demand for thin film-based products, particularly with respect to transdermal drug-eluting patch products, and rapidly-dissolving strips. While we have been working in this area for some time, the acquisition of semi-automated coating equipment will allow us to screen more formulation approaches, and get our clients into the clinic faster with a commercially representative film-based product." Particle Sciences focuses on advanced drug delivery solutions, and is FDA registered and licensed for all schedules of controlled substances. Mr. Gwozdz added that "Particle Sciences already had cGMP hot-melt film extrusion capability and now with the addition of coating and drying capabilities for liquid-based formulations, our clients have access to a complete array of viable and scalable film-manufacturing technologies."

Particle Sciences is an integrated provider of drug development services. Particle Sciences focuses on BCS II/III/IV molecules, biologics and highly potent compounds through a variety of technologies including emulsions, gels, micro and nano-particulates, drug/device combination products, solid solutions and others. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic. The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania. Visit www.particlesciences.com , email [email protected] or contact us at (610) 861-4701 for information.

Suggested Articles

Armed with microrobots and magnetic fields, Pursue scientists are looking to the future of targeted drug delivery, starting with the colon.

Zosano will need to run additional studies and await an FDA inspection to address the agency's complete response letter on its migraine patch Qtrypta.

Nanoform Finland tapped Quotient Sciences to help run the first in-human trial of a drug developed using its 'nanoforming' technology later this year.